About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, June 6th, 2017

The QualityStocks
Daily Stock List


Destiny Media Technologies, Inc. (DSNY)

Wall Street Resources, Greenbackers, SmallCapVoice, Blaque Capital Stocks, Breaking Bulls, Bullseyestox, Stockhouse, and OTC Picks reported previously on Destiny Media Technologies, Inc. (DSNY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Destiny Media Technologies, Inc. provides services that enable content owners to securely display and distribute their audio and video content digitally via the internet. Its two major services are Clipstream® and Play MPE®. The Company has granted patents for secure distribution and watermarking and a pending patent for cross platform PC and mobile streaming. OTCQB-listed, Destiny Media Technologies is based in Vancouver, British Columbia.

Destiny’s Clipstream® is a video format that plays on any modern smart phone, tablet, internet, TV, or computer. Its Play MPE® provides a standardized method to securely and cost effectively distribute pre-release music to radio stations and other music industry professionals, before it is ready for sale.

The Company’s revenue and earnings growth has been lifted by the flagship Play MPE® system. At present, it produces roughly 99 percent of Destiny Media Technologies’ revenue. The Play MPE® system is being embraced by the music industry as the standard for securely moving their pre-release music to radio stations and other recipients.

In February 2017, Destiny Media Technologies announced that it launched the next generation of the player used in the Clipstream® hosting and reporting service. This version contains the first approach in the industry utilizing the graphics processing unit of different devices to enhance the presentation of video within the browser employing a browser technology called WebGL.

The new player can access resources unavailable to conventional technologies to upscale and enhance the video, improving the viewer experience. Initially designed for use in 3D rendering and game development, WebGL is a low-level 3D graphics API. It gives the Clipstream player access to powerful additional resources for enhancing and presenting video. In addition, the new player includes several other fixes and performance enhancements.

This past April, Destiny Media Technologies announced its financial results for its fiscal 2017 Q2 ended February 28, 2017. Highlights include Quarterly Revenue growing by 2 percent versus the prior year. It was the fifth consecutive Quarter over Quarter Revenue growth. Play MPE Revenue growth was 4 percent year over year. Net Loss for Q2 declined by 10 percent to ($68,205), or ($0.00) per share, in comparison a Net Loss of ($75,383), or ($0.00) during the prior year. 

Destiny Media Technologies, Inc. (DSNY), closed Tuesday's trading session at $0.18, even for the day. The average volume for the last 60 days is 7,390 and the stock's 52-week low/high is $0.13/$0.30.

Inspyr Therapeutics, Inc. (NSPX)

BUYINS.NET reported earlier on Inspyr Therapeutics, Inc. (NSPX), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. It is in human clinical trials for patients with several different tumor types. Inspyr Therapeutics’ team has substantial pharmaceutical industry and scientific experience. The Company lists on the OTCQB.

Inspyr Therapeutics is developing a novel technology platform. It combines a powerful therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. The innovative platform technology has the potential to work across a range of drugs that precisely target different cancers.  

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer) and has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.

At present, Mipsagargin is undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). Furthermore, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.

Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach.  This new program is focused on the treatment of gastric cancer. The Company has begun a preclinical study in gastric cancer PDX tumor models, which express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.

In addition, Inspyr Therapeutics plans to evaluate Mipsagargin in combination with DC101 (Cyramza® surrogate antibody). Paclitaxel and Cyramza® are approved for the treatment of gastric cancer. Inspyr expects to share initial results from this initial study in the second half of this year.

In March, Inspyr Therapeutics announced that it signed a commitment letter with Milost Global, Inc., agreeing to terms for a commitment of up to $100 million in total proceeds. Milost Global is a U.S. private equity firm. This agreement includes an investment from Milost of up to $25 million in common stock priced at a premium to the current share price and up to $75 million in convertible notes. The proceeds will be used to advance Inspyr Therapeutics’ clinical development plans and provide for working capital needs.

Last week, Inspyr Therapeutics and Lewis and Clark Pharmaceuticals announced that they entered into an agreement to create an integrated company with a proprietary platform propelling a pipeline of novel therapeutics. Lewis and Clark Pharmaceuticals is a privately-held biotechnology company. With this agreement, Inspyr Therapeutics will purchase Lewis and Clark in an all-stock transaction and will execute plans to leverage a team with considerable experience to advance an extensive pipeline of novel therapeutics. The Boards of Directors of both companies have unanimously approved the proposed agreement.

Inspyr Therapeutics, Inc. (NSPX), closed Tuesday's trading session at $0.52, up 7.21%, on 1,540 volume with 3 trades. The average volume for the last 60 days is 5,962 and the stock's 52-week low/high is $0.30/$5.01.

Intellinetics, Inc. (INLX)

OTC Markets reported on Intellinetics, Inc. (INLX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Intellinetics, Inc. is an Enterprise Content Management (ECM) software company based in Columbus, Ohio. The Company is a provider of a cloud-enabled document management platform – IntelliCloud™ – optimized for the massive Small to Medium Business (SMB) market segment and business teams within large enterprises. Established in 1994, Intellinetics lists on the OTC Markets Group’s OTCQB.

Intellinetics concentrates on cloud-based document solutions for the SMB market. The Company partnered with Intel to create the IntelliCloud Channel Program. This program makes it easy to add turnkey document workflow solutions to the copiers, productivity software and services they already provide. Intellinetics’ cloud-based computing software is customizable for every client. This makes it applicable to almost any industry. Intellinetics provides a low-cost delivery model. This allows for speedy implementation and decreased storage requirements.

IntelliCloud provides dealers a “deploy once, use many” innovation. One IntelliCloud customer sale/activation creates unlimited possibilities to add other software applications that deliver more value and increase revenue. The IntelliCloud™ Document Workflow Management suite permits Small and Midsize Enterprises (SMEs) to easily capture paper or digital documents and connect them to business processes to reduce costs. This is while increasing accessibility, security, as well as compliance.

Intellinetics’ focus is on IntelliCloud Program growth within three specific partner profiles. One is Office Equipment Dealers (OED) - Copier dealers who also provide value added software, service, and technology services. The second is ECM Value Added Reseller (VAR) - Expert ECM software, hardware and service providers. The third is Software Solution Providers - Enterprise Resource Planning (ERP) or other software applications with proprietary IntelliCloud Integration.

Recently, Intellinetics announced it integrated its IntelliCloud™ platform with Field2Base’s industry-leading Field Service Automation (FSA) suite. The combined solution joins in-field and back-office documents and workflow. This creates an end-to-end process letting customers of any size to truly go paperless in the field.

Field2Base (an authorized Verizon Wireless partner) supports tens of thousands of end-users within Small, Mid-Market, as well as Fortune 500 Business customers. Moreover, the two companies are launching first phase cross-marketing of the new integrated solution into existing customer bases and reseller channels.

Last month, Intellinetics announced its partnership with LMI Solutions (LMI) as a strategic distributor of its IntelliCloud™ platform and related services. LMI Solutions is an award-winning provider of Managed Business Services Infrastructure to the market. IntelliCloud is a benchmark addition to LMI’s managed service offerings and completely integrates with LMI’s hardware, managed print services, and solution business segments. 

Intellinetics, Inc. (INLX), closed Tuesday's trading session at $0.74, down 1.33%, on 2,100 volume with 2 trades. The average volume for the last 60 days is 5,010 and the stock's 52-week low/high is $0.4999/$1.09.

Yew Bio-Pharm Group, Inc. (YEWB)

Greenbackers reported previously on Yew Bio-Pharm Group, Inc. (YEWB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Yew Bio-Pharm Group, Inc., via its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM), handicraft products made from yew timber, and yew candle and soap made with yew essence oil in China. Established in 1996, Yew Bio-Pharm is headquartered in Xiangfang District, Harbin City, Heilongjiang Province, China.

The OTCQB-listed Company utilizes a patented, accelerated growth technology to hasten the growth and maturity and commercialization of yew trees. In addition, it operates production facilities to manufacture yew handicrafts.  Its patented Asexual Reproduction Method speeds up the commercial viability of a yew tree. Consequently, a yew tree can be used for commercialization starting in roughly three years, versus greater than 50 years for naturally grown yew trees.

Through this method, Yew Bio-Pharm can more than replenish the number of yew trees it cultivates and puts into production. The patented Asexual Reproduction Method was developed by Yew Bio-Pharm’s Founder and President, Mr. Zhiguo Wang. The Patent is valid through September 29, 2030.

Yew Bio-Pharm grows Japanese yew trees (also known in China as Northeast yew trees), taxus cuspidata, on mountain hillsides near Harbin. It cultivates them in four nurseries it operates close to Harbin. Raw material from the species of yew tree that Yew Bio-Pharm grows contains taxol, and TCM containing yew raw materials has received approval as a traditional Chinese medicine (TCM) in China for the secondary treatment of certain cancers.

Also, Yew Bio-Pharm has established a division to center on organic foods and dietary supplements. The Company’s objective is to develop new business opportunities in related industries.

Last month, Yew Bio-Pharm Group reported financial results for the three months ended March 31, 2017. Total Revenues for Q1 of 2017 decreased 8.6 percent to $7.9 million from $8.6 million a year ago. Sales of TCM raw materials was 32.2 percent of Total Revenues; Sales of yew trees amounted to 0 percent of Total Revenues.

Sales of handicrafts amounted to 0 percent of Total Revenues and Sales of "Others" segment consisting of yew candle, yew essence oil soap and pine needle extracts amounted to 67.8 percent of Total Revenues. Yew Bio-Pharm Group did not make sales of yew trees in Q1 of 2017, which was primarily attributable to its strategy adjustment to reserve more yew trees for future TCM raw materials sales.

Yew Bio-Pharm Group, Inc. (YEWB), closed Tuesday's trading session at $0.1894, up 5.22%, on 15,100 volume with 3 trades. The average volume for the last 60 days is 4,710 and the stock's 52-week low/high is $0.027/$1.00.

AudioEye, Inc. (AEYE)

Wall Street Mover, Wall Street Resources, BUYINS.NET, PennyStocks24, FreeRealTime, Monster Stocks, and TheMicrocapNews reported earlier on AudioEye, Inc. (AEYE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AudioEye, Inc.’s concentration is on improving the mobility, usability, and accessibility of all Internet-based content. This is through the development, sale, licensing, and use of its proprietary accessibility technologies. AudioEye’s objective is transforming how the world experiences digital content through building leading-edge technology to make all digital content easier to consume and compliant with accessibility standards. AudioEye has offices in Tucson, Arizona; Atlanta, Georgia; and Washington, D.C.

The Company has developed patented Internet content publication and distribution software. It allows for the conversion of any media into an audio-accessible format. Additionally, it permits real-time distribution to end-users on any Internet-connected device.

AudioEye is the creator of the world’s first and only cloud-based cross-platform/cross-browser screen reader solution for web browsing. The Company’s emphasis is to provide solutions that create better and more complete access to the Internet, print, broadcast, and other media. This is regardless of one’s network connection, device, location, or specific abilities.

AudioEye has its Ally™ platform. The Ally+ product enables the Company’s clients to reach more customers, build more brand loyalty, keep more customers and secure more repeat business. AudioEye launched its Ally™ platform, which provides a complete, multi-layered solution for organizations looking to comply with Section 508 best practices.

AudioEye solutions also include all-inclusive E-Learning and E-Commerce systems, along with an assortment of Internet publishing products and services. Its technology utilizes its patented architecture to deliver a fully accessible audio equivalent of a visual website or mobile website in a compliant format that can be navigated, used, interacted with, and transacted from without the use of a monitor or mouse, by individuals with visual impairments.

The AudioEye Platform is a completely scalable cloud-based solution. For individuals with hearing impairments, the Company’s technology provides captioning for websites. Also, the challenges of reaching those with other impairments are addressed by the technology platform. The platform offers publishers complete control over the accessibility of their web assets and web environments. This lets the publisher recognize, remediate, and report its real-time accessibility status.

In May, AudioEye announced a new working agreement with Finalsite, the leader in K12 independent and international school web development and hosting, which serves over 2,000 schools globally. AudioEye has expanded its reach into the education space with many contracts with school districts, universities, community colleges, and vocational schools nationwide.

Today, AudioEye announced continued strong new customer bookings in its second quarter to date, following record Q1 bookings of $1.7 million. Furthermore, it announced further growth in its qualified new business pipeline, to $6.8 million, from $5.3 million at March 31, 2017.

AudioEye, Inc. (AEYE), closed Tuesday's trading session at $0.18625, down 1.14%, on 38,733 volume with 11 trades. The average volume for the last 60 days is 130,068 and the stock's 52-week low/high is $0.07/$0.37.


The QualityStocks
Company Corner


Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0304, up 27.73%, on 24,582,758 volume with 805 trades. The stock’s average daily volume over the past 60 days is 3,484,534, and its 52-week low/high is $0.0062/$0.142.

Singlepoint, Inc. today announces its initiative to develop a bitcoin payments solution in partnership with First Bitcoin Capital Corp. (OTC: BITCF). The two companies signed a Joint Venture agreement to develop and distribute a viable payments solution using block chain technology. First Bitcoin Capital is an industry leading Bitcoin and blockchain technology provider and SinglePoint has a deep history in distribution. The two companies believe this partnership will enable each company to focus on their core strengths to build and supply the best Bitcoin solution available.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint and First Bitcoin Capital Partner Up In An Effort To Solve Payment Problems in the Cannabis Industry Through Bitcoin and blockchain alternative payment technology

SinglePoint CEO Featured on MoneyTV with Donald Baillargeon, 6/2

NetworkNewsWire Announces Publication on Several Stocks Applying Their Innovations to the Evolving Marijuana Industry

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $1.04, up 0.97%, on 63,826 volume with 98 trades. The stock’s average daily volume over the past 60 days is 67,345 and its 52-week low/high is $0.12/$2.75.

ChineseInvestors.com today announces that it has formally engaged Launch Haus, LLC ("Launch Haus"), venture building firm and digital holding company, based in Scottsdale, AZ, specializing in direct response marketing including digital, ecommerce, and direct sales channels. Launch Haus will play an integral part in directing the Company's organization and launch of its direct-to-consumer ecommerce and network marketing business divisions.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

ChineseInvestors.com, Inc. Engages Venture Building Firm 'Launch Haus, LLC' to Drive its Hemp-based eCommerce and Network Marketing Business Divisions

ChineseInvestors.com, Inc. to Attend 6th Annual SeeThru Equity Microcap Investor Conference

ChineseInvestors.com, Inc. Announces its New Subsidiary Chinesehempoil.com, Inc. and the Launch of its First Premium Hemp Health Product Line 'OptHemp'

Players Network, Inc. (PNTV)

The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.0975, up 30.70%, on 14,028,685 volume with 1,165 trades. The stock’s average daily volume over the past 60 days is 2,066,828, and its 52-week low/high is $0.0023/$0.078.

Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.

Green Leaf Farms Holdings, LLC (Green Leaf)

Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.

Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.

They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.

Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.

Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.


WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.

Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.

WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.

By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.

Marijuana and Media Strategy

While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer

Players Network, Inc. Company Blog

Players Network, Inc. News:

Player's Network, Inc. CEO Featured on MoneyTV with Donald Baillargeon, 6/2

Player's Network, Inc. Subsidiary Awarded Two Nevada Recreational Marijuana Licenses

Player's Network Subsidiary Awarded Medical Marijuana Licenses

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.4031, up 3.36%, on 29,565 volume with 14 trades. The stock’s average daily volume over the past 60 days is 146,902 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub (ORHB) Enhances Leading Data Analytics Platform with Integration of Sterilization Process Module

ORHub (ORHB) Appoints New Chief Operating Officer to Facilitate Growth Strategies

Significant Milestone Helps ORHub (ORHB) Deliver Cost-cutting Insight to Health Care Providers

CD International Enterprises, Inc. (CDII)

The QualityStocks Daily Newsletter would like to spotlight CD International Enterprises, Inc. (CDII). Today, CD International Enterprises, Inc. closed trading at $0.0035, up 16.67%, on 2,229,250 volume with 35 trades. The stock’s average daily volume over the past 60 days is 2,664,711 and its 52-week low/high is $0.0001/$6.00.

CD International Enterprises, Inc. (CDII) is a U.S.-based company operating in two primary business segments: mineral trading and consulting services. Headquartered in Deerfield Beach, Florida, with operations centering on the rapid growth of the Chinese economy, CDII allows prospective investors to participate in the considerable opportunities presented by emerging markets in both the People's Republic of China and the Americas.

CDII Minerals, Inc., a wholly-owned subsidiary of CD International, serves as its commodities trading division. Through CDII Minerals, CDII sources, aggregates and distributes iron ore, manganese ore and scrap metals for clients operating throughout China. The company maintains a strategic position between its North and South American suppliers and its Chinese clients, allowing it to both address a niche market opportunity and facilitate more efficient transactions for its customers.

In addition to its mineral trading services, CDII has found success in offering a comprehensive suite of consulting services related to the unique characteristics of business operations in China. In December 2016, the company announced its entry into a two-year corporate agreement with a China-based subsidiary of Everbright International Construction Engineering Corporation, through which CDII will provide information related to foreign and domestic constructions, project tending offers, government communications and local networks. In January 2017, CDII announced its entry into a similar agreement with Zhangjiajie Shengshi Agricultural Development Company, through which it will provide consulting services related to a number of business developments, including the development of a distribution business centered on cannabidiol extract derived from industrial hemp.

Per the company's website, CDII's greatest strength lies in the quality of its personnel, which includes a culturally diverse group of professionals operating within the United States, as well as in China and emerging markets throughout the Americas. Dr. James Wang has served as CEO and chairman of the CDII board since August 2006. He has also served as CEO and chairman of China Direct Investments since January 2005. Wang brings a wealth of experience in corporate finance in the U.S. capital markets to the CDII management team, and his work in the identification and acquisition of China-based growth companies has played an instrumental role in the execution of CD International's strategic vision for over a decade.

Wang is joined on the CDII management team by Controller Shirley Xu and Vice President of Business Development Katie Zhao. Xu has served as the company's controller since January 2013, assuming a range of responsibilities including internal control, general ledger accounting oversight, and financial reporting for CDII and its subsidiaries. She is also responsible for SEC financial reporting for the company's consulting segment clients.

Katie Zhao has served in her current role with CD International since January 2012. Prior to becoming VP of business development, she served as the company's project manager from 2007 to 2009 and as senior account executive from 2010 to 2011. From these positions, Zhao played a key role in the establishment of CDII's U.S. distribution channels for its Chinese clients, as well as the implementation of a network connecting the company's U.S. and China-based offices. Disclaimer

CD International Enterprises, Inc. Blog

CD International Enterprises, Inc. News:

CD International Enterprises Signs Full Corporate Offer to Purchase 1.2 Million Tons of Metallurgical Grade Bauxite

CD International Enterprises Enters Wholesale Distribution Agreement With Leading Global Supplier of Cannabidiol/Hemp-Derived Products

CD International Enterprises (OTC: CDII) Enters a Full Corporate Offer To Purchase Copper Cathodes Valued at Approximately $330 Million


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(SLNOW) +110.43%


(PNTV) +30.70%


(SING) +27.73%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251